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ATP productionRecent evidence implies that impairedmetabolism of glutathione has a role in the pathogenesis of nephropathic
cystinosis. This recessive inherited disorder is characterized by lysosomal cystine accumulation and results in
renal Fanconi syndrome progressing to end stage renal disease in the majority of patients. The most common
treatment involves intracellular cystine depletion by cysteamine, delaying the development of end stage renal
disease by a yet elusive mechanism. However, cystine depletion does not arrest the disease nor cures Fanconi
syndrome in patients, indicating involvement of other yet unknown pathologic pathways. Using a newly
developed proximal tubular epithelial cell model from cystinotic patients, we investigate the effect of cystine
accumulation and cysteamine on both glutathione and ATP metabolism. In addition to the expected increase in
cystine and defective sodium-dependent phosphate reabsorption, we observed less negative glutathione redox
status and decreased intracellular ATP levels. No differences between control and cystinosis cell lines were
observed with respect to protein turnover, albumin uptake, cytosolic and mitochondrial ATP production, total
glutathione levels, protein oxidation and lipid peroxidation. Cysteamine treatment increased total glutathione in
both control and cystinotic cells and normalized cystine levels and glutathione redox status in cystinotic cells.
However, cysteamine did not improve decreased sodium-dependent phosphate uptake. Our data implicate that
cysteamine increases total glutathione and restores glutathione redox status in cystinosis, which is a positive
side-effect of this agent next to cystine depletion. This beneﬁcial effect points to a potential role of cysteamine as
anti-oxidant for other renal disorders associated with enhanced oxidative stress.; GSSG, oxidized glutathione;
mortalized proximal tubular
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Since cysteamine therapy has become available for patients with
nephropathic cystinosis (MIM219800) in the early 1980s, quality of life
for these patients has greatly improved [1,2]. The most frequent and
most severe form, infantile cystinosis, is characterized by the develop-
ment of renal Fanconi syndrome in the ﬁrst year of life and leads to end
stage renal disease in the ﬁrst decade of life when untreated [3].Mutations in the CTNS gene, encoding for lysosomal cystine transporter
cystinosin are the cause of cystinosis [4]. Lysosomal accumulation of
cystine, which is the hallmark of this autosomal recessive disorder, can
bedepletedby the amino-thiol cysteamine [5]. Although treatmentwith
cysteamine substantially decreases intracellular cystine accumulation,
renal Fanconi syndrome is not cured, but end stage renal disease can be
postponed in the majority of the patients. On the other hand, recent
ﬁndings in a ctns−/− mouse model suggest that cystine accumulation
itself is not sufﬁcient for the development of renal aberrations [6].
Several mechanisms have been postulated to link lysosomal cystine
accumulation in cystinosis with renal tubular defects, such as impaired
ATP synthesis [7,8], involvement of altered glutathione (GSH) metab-
olism [9,10] and increased apoptosis rate [11,12].
Decreased levels of total GSH in cystinotic ﬁbroblasts during
exponential growth were ﬁrst reported by Chol et al. [9]. This ﬁnding
was conﬁrmed in primary proximal tubular cells derived from urine
[13]. In contrast, normal total GSH levels but increased oxidized GSH
(GSSG) levels have been reported in cystinotic ﬁbroblasts grown to
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immortalized with HPV E6/E7 [10,14,15]. Together with the ﬁnding of
elevated urinary 5-oxoproline (pyroglutamic acid), a precursor for
GSH synthesis, these data suggested that impaired lysosomal cystine
efﬂux in cystinosis affects GSH metabolism, likely via impairment of
γ-glutamyl-cycle [16]. Alterations in GSSG/2GSH ratio affect intracel-
lular metabolic functions and point towards increased intracellular
oxidation [17].
In addition to alterations in ATP-dependent GSH synthesis, de-
creased intracellular ATP levels have been reported in cells loaded with
cystine dimethylester (CDME) [7]. Coor et al. used this model to
postulate that decreased ATP synthesis accounts for decreased sodium
gradient and, consequently, inﬂuences tubular reabsorption in cysti-
nosis. Despite the limitations of the CDMEmodel [18], this hypothesis is
still pending, since decreased ATP levels in cystinotic ﬁbroblasts and
proximal tubule cells were reported [8,13]. More recently, decreased
ATP generation capacity was shown in cystinotic renal proximal tubular
cells [19].
Despite extensive research, deﬁnite conclusions whether alterations
in GSH and/or ATP status are involved the pathogenesis of cystinosis are
lacking. In addition, the question remains why cysteamine treatment
postpones the progression of renal disease and has no curative effect on
Fanconi syndrome, despite the decrease in cystine levels. Likely, the
anti-oxidative effect of cysteamine plays a role in this process, as
cysteamine was demonstrated to increase GSH levels in mouse
ﬁbroblasts [20]. This study focuses for the ﬁrst time on the inﬂuence
of cysteamine on both GSH and ATPmetabolism in vitro using a recently
developed conditionally immortalized proximal tubular epithelial cell
line (ciPTEC) [21,22]. Here, 4 control and 10 cystinotic ciPTEC lines with
different mutations in the CTNS gene were developed from healthy
controls and patients, using identical methodology. This allowed a
valuable comparison of their metabolic status in presence and absence
of cysteamine to improve our insight in the mechanism of cysteamine
efﬁcacy in cystinosis.
2. Materials and methods
2.1. Cell culture
Primary cell lines were cultured from urine of 4 healthy controls (age
60–152 monthsold) and10patientswith cystinosis (age11–209 months
old) after approval of the study design by the Institutional Review Board
and obtaining written informed consent by the parents of all subjects as
describedpreviously [22].Diagnosis of cystinosiswasmadebymeasuring
elevated intracellular cystine levels in polymorphonuclear granulocytes
and conﬁrmed bymolecular analysis of the CTNS gene (Table 1). Control
cell lineswereobtained frompediatric healthyvolunteerswithno clinical
history of renal disease, nor with any other chronic disease. To maintain
cell proliferation, primary cell lines were transfected with SV40T tsTable 1
Clinical information and CTNS mutation of the patients from whom ciPTEC were
derived.
Cell line Agea (months) Sex Mutation
cys1 78 m [57 kb del]+[57 kb del]
cys2 129 m [57 kb del]+[57 kb del]
cys3 134 f [c. 141–24TNC]+[c. 141–24TNC]b
cys4 50 m [57 kb del]+[57 kb del]
cys5 47 m [57 kb del]+[57 kb del]
cys6 174 m [57 kb del]+[c.696_697insC]
cys7 11 f [57 kb del]+[c.927_928insG]
cys8 78 f [57 kb del]+[c.del18_21GACT]
cys9 96 f [57 kb del]+[c.665ANG]
cys10 209 m [57 kb del]+[57 kb del]
m, male; f, female.
a Age in months at collection of urine.
b From Ref. [49].A58 (SV40T) and hTERT (human telomerase reverse transcriptase)
followed by subcloning procedures to obtain homozygous cell popula-
tions [22–24]. Proximal tubular origin of all tested cell lines was
conﬁrmed as described previously [22] by demonstrating presence of
aminopeptidase N, aquaporin1, P-glycoprotein and dipeptidyl peptidase
IV using Western blotting. Additionally, sodium-dependent phosphate
transport and alkaline phosphatase activity were analyzed. Of each
donor, one subclone was selected on the basis of expression pattern and
activity of the proximal tubular characteristics and used for further
experiments, unless mentioned otherwise. In total, subcloned ciPTEC
were used from 10 cystinotic patients and 4 healthy controls. Routinely,
cells were maintained at permissive temperature of 33 °C (proliferating
cells). To decrease expression of SV40T, cells were transferred to 37 °C
and allowed to mature for up to 10 days (matured cells).
2.2. Cell proliferation
To compare cell proliferation rate between control (n=4) and
cystinotic (n=6) cell lines, cells were counted at several stages up to
10 days of maturation at 37 °C. Data are expressed as percentage
increase in cell number when transferred from 33 to 37 °C.
Additionally, total intracellular protein content was measured using
Biorad Protein assay (Biorad Laboratories, Germany) during matura-
tion of cells cultured in 24 well plates.
Protein synthesis was determined at day 10 of maturation by
measuring 3H-Leucine (3H-Leu) incorporation. Control and cystinotic
ciPTECwere cultured in triplo in 24well plates in thepresence of 3H-Leu
(3 μCi/ml; GE Healthcare, UK) supplemented tissue culture medium for
2, 6, 16 and 24 h. Cells were washed using ice-cold PBS and proteins
were precipitated using 10% (w/v) trichloroacetic acid. Proteins were
dissolved in 400 μl NaOH (0.3 M) and subsequently to neutralization
with80 μl HCl (1.5 M) radioactivitywasmeasured using a TriCarb liquid
scintillation counter (Perkin Elmer, USA). Using speciﬁc activity of 3H-
Leu, incorporation of Leu was calculated and expressed as pmol/mg
protein. Cell cycle analysis was performed on proliferating andmatured
cells (control n=3; cystinosis n=6), by harvesting cells using trypsin
and ﬁxation in 70% (v/v) ice-cold ethanol. Subsequently, cells were
stained using propidium iodide (10 μg/ml) in citrate buffer (0.2 M
Na2HPO4, 0.1 Mcitric acid) in thepresenceof RNAse (5 μg/ml). Cell cycle
was determined by ﬂow cytometry and presented as percentage of the
cells in the S-phase of mitosis.
2.3. Albumin uptake in ciPTEC
Albumin uptake was performed as previously described [22] by
analyzing BSA-FITC uptake by ﬂow cytometry. Brieﬂy, ciPTEC of
controls (n=4) and cystinotic patients (n=7) were incubated for
30 min with 50 μg/ml BSA-FITC. Mean ﬂuorescence intensity was
presented as mean±SEM. To conﬁrm that albumin uptake was
megalin dependent, we performed receptor associated protein (RAP)
inhibition assays on BSA-FITC uptake. RAP was kindly provided to us
by Dr. M. Nielsen (University of Aarhus, Denmark).
2.4. Thiols and disulﬁde determination
Matured ciPTEC were harvested using trypsine/EDTA, washed twice
in PBS and pellets were shock frozen in liquid nitrogen and stored at
−80 °C until further processing. Total intracellular content of cysteine,
cystine, GSH and GSSG was measured using HPLC as described before
[10]. Cystine levels were measured in all control (n=4) and cystinotic
(n=10) ciPTEC aftermaturation for 10 days at 37 °C. To test the effect of
cysteamine on intracellular cystine levels, we performed a series of
experiments varying its concentration (0.2; 1; 2 mM) and time of
incubation (0.5; 1; 2; 4; 8; 16; 24; 48 h). To study the effect of long-term
cysteamine treatment (1 mM) on intracellular thiol and disulﬁde levels,
control (n=4) and cystinotic (n=7) ciPTEC were incubated in the
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supplemented culture medium was refreshed every 6 h. Data are
expressed as nmol thiol/mg protein (±SEM). Furthermore, correlations
between intracellular cystine and GSSG levels were determined.
2.5. Redox status calculation
Redox status (Eh) of GSSG/2GSH pool was calculated using the Nernst
equation according to Schafer and Buettner [17]:(Eh (mV)=E0−RT/nF
log ([GSH]2/[GSSG]),where E0 for pH 7.4=−264 mV; RT/nF=30 and
concentrations for GSH andGSSG inM are calculated assuming that 1 mg
protein corresponds to a cellular volume of 5 μl [25].
2.6. Determination of ROS and oxidation status
Possible alterations in reactive oxygen species (ROS) formation in
cystinotic ciPTEC were analyzed using the probes 5-(and-6)-chlor-
omethyl-2,7-dichlorodihydroﬂuorescein diacetate acetyl ester (CM-
H2DCFDA), and hydroethidine (HEt) [26]. Measurements were
performed in matured control (n=4) and cystinotic (n=10) ciPTEC.
The production of ROS using CM-H2DCFDA was detected in ciPTEC
using a 96 well assay [27]. Matured ciPTEC were washed in HEPES–
Tris buffer (NaCl (132 mM), KCl (4.2 mM), CaCl2 (1 mM), MgCl2
(1 mM), D-glucose (5.5 mM), Hepes (10 mM), pH 7.4 using Tris) and
incubated for 15 min in the dark with 80 μl CM-H2DCFDA (10 μM).
Esterase hydrolyzes CM-H2DCFDA to form intracellular trapped CM-
H2DCF, which can oxidize to ﬂuorescent CM-DCF, e.g. by the action of
ROS. Cells were washed twice in HEPES–Tris buffer and incubated in
the absence and presence of H2O2 (0; 10; 100 and 1000 μM) as a
positive control to stimulate oxidation and to verify the sensitivity of
the assay. Formation of CM-DCF as a marker for oxidation was
monitored immediately and monitored for 15 min on Victor3V
multilabel counter (ex464 nm, em530 nm; Wallac, Perkin Elmer).
Additionally, one set of samples was pre-incubated with 1 mM
cysteamine for 2.5 h at 37 °C. Basal and H2O2 stimulated CM-H2DCF
oxidation was calculated as the slope of ﬂuorescence intensity
increase versus time and expressed as oxidation rate (±SEM) with
untreated cells set at 100% after correction for protein content.
Alternatively, matured ciPTEC were loaded with HEt (10 μM) in
HEPES–Tris buffer for 15 min in 24well plates in presence or absence of
the positive control rotenone (100 nM). Rotenone stimulates superox-
ide production by inhibiting complex I of the oxidative phosphorylation
system [28]. The ﬂuorescent oxidation products of non-ﬂuorescent HEt,
2-hydroxyethidium and ethidium, were detected in ciPTEC using ﬂow
cytometry after harvesting the cells using trypsine/EDTAandwashing in
PBS. Additionally, one set of samples was pre-incubated with cyste-
amine (1 mM) for 2.5 h in culturemedium. Data are expressed asmean
ﬂuorescence intensity (±SEM).
Possible changes in protein oxidation and lipid peroxidation were
investigated by determining the amount of butylated protein and F2-
isoprostane, respectively. Oxidative stress can lead to the introduction
of carbonyl groups in proteins, detectable by immunoblotting using
the Oxyblot™ protein oxidation detection kit (Millipore, USA).
Matured ciPTEC of 4 controls and 7 patients were examined according
to the manufacturer's protocol. After immunoblotting and develop-
ment using ECL Western blotting substrate (Thermo Fisher Scientiﬁc,
USA), pixel intensity for each cell line was analyzed using ImagePro
(MediaCybernetics) and corrected for GAPDH expression.
Intracellular concentrations of F2-isoprostanes (8-iso-prostaglan-
din F2α VI; iPF2 α-VI) were determined as marker of oxidative stress
using LC-MS/MS. Brieﬂy, butylated hydroxytoluene (0.08% (v/v)) was
added to cell pellets to prevent auto-oxidation, and deuterated
internal standard (0.2 ng iPF2α-d4, Cayman) was added to correct for
loss during sample preparation. Then, the cells were sonicated for
3×10 s at 4 °C to lyse the cells. Afterwards, KOH was added (ﬁnal
concentration of 1.3 M) and the lysate was incubated for 1 h at 40 °C.Formic acid (20% (v/v)) was added to adjust to pH 4.5 and samples
were prepared using solid-phase extraction as reported previously
[29]. The eluate was dried under a stream of nitrogen at room
temperature and redissolved in 100 μl acetonitrile (10% (w/v)). F2-
isoprostanes were analyzed by a 4000 Qtrap (PE Sciex, Canada) MS.
The concentration of iPF2α-VI was calculated using a standard curve
of iPF2α-VI (Cayman) and corrected for amount of protein. Data are
expressed as ng/mg protein.
2.7. ATP metabolism
Intracellular ATP levels were measured in control (21 separate clones
of 4 donors) and cystinotic (50 separate clones of 10 donors) matured
ciPTEC using ATP Bioluminescence Assay Kit HSII (Roche, Germany) as
described before [15]. The effect of cysteamine on intracellular ATP levels
was determined in cystinotic ciPTEC (n=4) cultured in presence of
cysteamine (1 mM) for 48 h, with medium replacement every 6 h.
Mitochondrial and cytosolic ATP production were measured by
transfecting proliferating ciPTEC with baculovirus containing cDNA
for mitochondria targeted luciferase or luciferase without targeting
sequence as described before [30]. Brieﬂy, proliferating ciPTEC
(control n=2, cystinosis n=2; both measured in 4-fold) were
cultured on coverslips and transfected for expression of cytosolic or
mitochondrial luciferase. After two additional days of culturing at
37 °C, ATP production in intact ciPTEC was determined by perfusing
the cells with 25 μM luciferin in Hepes–Tris buffer and measuring the
luciferase luminescence using photomultiplier tube. After reaching a
stable signal, cells were perfused with digitonin (DIG; 100 μM) and
excess ATP (10 mM). Permeabilization of cellular membranes by DIG
in the presence of excess ATP resulted in a peak in luminescence
signal, which was limited by total luciferase present in the cells. Basal
cytosolic and mitochondrial ATP production are expressed as
percentage of the peak in luminescence after DIG treatment (±SEM).
Cytosolic ATP production from glycolysis was measured by deter-
mining pyruvate production in conditioned culture medium of ciPTEC
and by measuring ATP levels in the presence of inhibitors of glycolysis
[8,31]. Brieﬂy, matured ciPTEC (control n=5; cystinosis n=8) were
cultured in serum-free culture medium for 2.5 h in presence or absence
of glycolysis inhibitors sodium iodoacetate (SIA; 0.02 mM) or deoxy-
glucose (DOG; 100 mM). Pyruvate production was subsequently
measured in culture medium using lactate dehydrogenase (100 U/ml;
Roche, Germany) after addition of NAD+ (2 mM; Roche, Germany) at
pH 9.5. Formation of NADH is directly correlated to glycolytic pyruvate
production and was analyzed by measuring the absorbance at 340 nm
on Victor3V Multilabel Counter (Wallac, Perking Elmer, USA).
2.8. Phosphate transport and content
Intracellular phosphate levelswere determined in duplo in cell pellets
of matured control (n=3) and cystinosis (n=6) ciPTEC to test whether
decreasedATP levels couldbe a result of decreasedphosphate availability.
Data are expressed as mM phosphate/mg protein±SEM. Furthermore,
alterations in sodium-dependent phosphate uptake in cystinosis ciPTEC
were investigated using radio-labeled 32PO4 as describe before [22]. Km
and Vmax values were determined using phosphate saturation curves in
control (n=4) and cystinotic (n=5) ciPTEC with GraphPad Prism
(version 5.03, GraphPad Software Inc.). Further, experiments were
performedwith a pre-incubation of cysteamine (1 mM) for 2 h, followed
by theuptakeof K2HPO4 (0.22 mM) inpresenceor absenceof cysteamine.
2.9. Statistical analysis
To compare cystinosis and control ciPTEC and the effect of
cysteamine, appropriate unpaired or paired Student's t-test were used
for statistical analysis. Correlations were analyzed using Spearman test.
Fig. 2. Albumin uptake in ciPTEC. (A) Albumin uptake in both control and cystinotic
ciPTEC was decreased by megalin-ligand RAP in a concentration dependent manner.
(B) Flow cytometry analysis of BSA-FITC uptake in control cell lines (n=4) and
cystinotic cell lines (n=7) demonstrated that albumin uptake in cystinotic cell lines
was normal compared to control ciPTEC (p=0.75). Gray dots represent cystinotic
patients with a homozygous 57 kb deletion.
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3.1. Cell culture and proliferation
Primary cell lines derived from urine were successfully transfected
using SV40T and hTERT vectors and subcloned as described before [22].
This resulted in 14 ciPTEC clones, derived from 4 individual control
subjects and 10 cystinosis patients (Table 1). The presence of alkaline
phosphatase activity conﬁrmedproximal tubular origin andwas similar in
control and cystinosis cell lines (activity in control 2.5±1.6 vs. cystinosis
2.3±1.2 mU/mg protein). Additionally, the expression of the proximal
tubular cell markers aminopeptidase N, aquaporin1, P-glycoprotein and
dipeptidyl peptidase IV were similar in all cell lines (data not shown).
Transfection with SV40T resulted in cell lines proliferating at 33 °C, while
the disappearance of the SV40T antigen expression at 37 °C during
10 days resulted in cell maturation. The additional transfection using
hTERT prevented the occurrence of replicative senescence.
Proliferation of control and cystinosis ciPTEC was monitored for
10 days at 37 °C by cell count and protein determination. Both control
and cystinosis ciPTEC proliferated similarly up to ~3 days (Fig. 1A). At
this stage, SV40T expression was decreased as previously shown [22].
The total cell population was doubled at the end of the maturation
period in both cell populations. Intracellular protein content of both
control and cystinosis ciPTEC reached a plateau at day 6 of maturation
(Fig. 1B). Both control and cystinosis ciPTEC readily incorporated 3H-
Leu between days 8 and 10 of maturation, indicating the absence of
any difference in protein synthesis (Fig. 1C). Cell cycle analysis using
propidium iodide staining indicated that control and cystinosis cells
had similar stages of cell division. At 33 °C, 11.0% (±0.5) and 68.3%
(±2.3) of control ciPTEC compared to 12.8% (±2.5) and 64.3 (±5.6) of
cystinosis ciPTEC were in the S-phase or G1/G0 phase respectively.
After 10 days of maturation at 37 °C the percentage of cells in S-phase
was decreased to 3.0% (±0.8; pb0.01) and 5.0% (±0.7; pb0.05),
respectively. The percentage of G1/G0 phase, indicative for differen-
tiation, increased after maturation to 73.7% (±5.9) for control ciPTEC
and 70.7% (±5.5) for cystinosis cells. No difference was observed
between cystinosis and control cells. Further, no signiﬁcant differ-
ences in cell division rate nor in intracellular protein content or
incorporation were observed between control and cystinosis ciPTEC,
allowing the expression of metabolic measurements as a function of
protein content in further assays.
3.2. Albumin uptake in ciPTEC
Albumin uptake in both control and cystinotic ciPTECwas decreased
by megalin-ligand RAP in a concentration dependent manner, suggest-
ing endocytic uptake of albumin via megalin (Fig. 2A). To test whetherFig. 1. Cell proliferation of control and cystinotic ciPTEC. (A) Cell proliferation decreases at
(B) Protein content as expressed per well plateaus at approximately 6 days after matura
maturation. Matured control (closed circles) and cystinotic (open circles) ciPTEC show noalbumin uptake was affected in cystinotic ciPTEC, we performed ﬂow
cytometry analysis of BSA-FITC uptake in 4 control cell lines and 7
cystinotic cell lines in two independent experiments in triplo (Fig. 2B).
Both experiments demonstrated that albumin uptake in cystinotic cell
lines was comparable to control ciPTEC (p=0.75).
3.3. Intracellular thiol and disulﬁde content
Intracellular cystine levels in matured ciPTEC were signiﬁcantly
increased in the cystinosis ciPTEC clones derived from 10 cystinosis
patients compared to 4 control ciPTEC (5.2±0.7 versus 0.14±0.02,
respectively; pb0.01; Fig. 3A). Each point represents one patient or
control cell line, measured at least in 2 separate assays. The dose-
dependent effect of cysteamine on intracellular cystine levels in
cystinosis cell lines was determined, demonstrating that 1 mM
cysteamine normalized the cystine content within 30 min after
addition and for a period up to 8 h (data not shown). By refreshing
the cysteamine supplemented culture medium every 6 h during 48 h,
cystine levels in cystinosis ciPTEC were maintained in the control
range (0.26±0.07, p=0.23; Fig. 3B). Free cysteine levels were also
signiﬁcantly increased in cystinosis ciPTEC (7.2±1.2 versus 2.4±0.5,
pb0.05). Similarly, free cysteine levels were normalized upon
cysteamine treatment (2.1±0.5, p=0.87; Fig. 4A).
TotalGSH levelswere similar in cystinosis and control ciPTEC (34±5
and 35±6, respectively, p=0.86; Fig. 4B). Remarkably, due to
cysteamine treatment for 2 days, total GSH levels were signiﬁcantlyapproximately 3 days after raising the temperature to 37 °C to induce cell maturation.
tion induction. (C) Twenty-four hour incorporation of 3H-Leu measured at day 9 of
differences in cell number and protein synthesis.
Fig. 3. Cystine accumulation in ciPTEC. (A) HPLC analysis reveals signiﬁcantly elevated
cystine levels in single clones frommatured cystinotic ciPTEC derived from eight donors
compared to control ciPTEC clones derived from four donors (pb0.01). (B) Treatment
with 1 mM cysteamine for 2 days (replacement every 6 h), restores cystine levels in
cystinotic ciPTEC. Gray dots represent cystinotic patients with a homozygous 57 kb
deletion. ⁎⁎pb0.01.
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pb0.01) ciPTEC, suggesting that cysteamine treatment increased
cellular capacity to deal with oxidative stress (Fig. 4B).
GSSG levels were signiﬁcantly increased in cystinosis cells (0.15±
0.04 versus 0.66±0.16; pb0.05) and correlated with intracellular
cystine levels (pb0.01; r2=0.76; Fig. 4C). Cysteamine treatment tended
to increase GSSG in both control and cystinosis ciPTEC, however this
effectwasnot statistically signiﬁcant in cystinosis cells. Using theNernst
equation according toSchafer andBuettner [17],weestimated the redoxFig. 4. Intracellular thiol levels in ciPTEC. (A) Free cysteine levels are increased inuntreated
cystinotic ciPTEC and decreased upon cysteamine treatment for 2 days (cysteamine).
(B) Total GSH levels are similar in control and cystinotic ciPTEC and increased upon
cysteamine treatment. (C) There is a signiﬁcant correlation between intracellular cystine
levels andGSSG levels in cystinotic ciPTEC, suggesting that lysosomal cystine accumulation
inﬂuences intracellular GSH redox status (pb0.01; r2=0.76). (D) Redox status (Eh (mV)),
calculated using the Nernst equation, is less negative in cystinotic cells. Cysteamine
treatment restores the redox status in cystinotic cells. Black bars, control; white bars,
cystinosis. ⁎pb0.05; ⁎⁎pb0.01.status of theGSSG/2GSHcouple in ciPTEC.Our calculations revealed that
the reduction potential was signiﬁcantly less negative in matured
cystinosis ciPTEC (−270±4 versus −251±1; pb0.01; Fig. 4D). The
reduction potential in cystinosis ciPTEC was restored to control values
upon cysteamine treatment (−269±3; p=0.43).
3.4. Intracellular ROS production and oxidation status
To get an indication whether increased redox status was a result of
increase in ROS production, oxidation was measured under basal and
stressed conditions using the probes CM-H2DCFDA and HEt. Oxidation
of CM-H2DCF to CM-DCF occurred linear in time and dose-depen-
dently increased upon stimulation with H2O2 (data not shown). Basal
oxidation of CM-H2DCF did not differ between control and cystinosis
ciPTEC (ﬂuorescence intensities of 2515±97 and 1988±381,
respectively; p=0.40; Fig. 5A). H2O2 tended to increase the formation
of CM-DCF in cystinosis cells compared to control cell lines, reaching
statistical signiﬁcance at 1000 μM (pb0.05; Fig. 5B). Treatment of
control and cystinosis cells with 1 mM cysteamine for 2.5 h did not
alter basal and/or H2O2-stimulated CM-H2DCF oxidation (data not
shown).
No signiﬁcant alterations in HEt oxidation were observed in
control versus cystinosis ciPTEC (1.3±0.4 versus 3.4 (±1.1), p=0.27;
Fig. 5C). The addition of rotenone, a potent stimulator for mitochon-
drial ROS production, caused a signiﬁcant increase in HEt oxidation
levels, indicating that cells were not in a maximum state of oxidation
(pb0.05). Cysteamine treatment for 2.5 h did not alter HEt oxidation
in control and/or cystinosis cells (data not shown). Using the
Oxyblot™ protein oxidation detection kit, we investigated possible
changes in protein oxidation between control and cystinosis ciPTEC.
However, no differences were detected (intensity values of 0.67±
0.05 and 0.82±0.07, respectively; p=0.19). In addition, iPF2α-VI,
one of the major F2-isoprostanes, was determined as a marker for
fatty acid oxidation. Levels of iPF2a-VI were comparable in control
(0.33±0.1) and cystinosis ciPTEC (0.35±0.1; p=0.79).
3.5. ATP metabolism
Intracellular ATP levels were measured in 21 characterized clones
of the 4 control matured ciPTEC and 50 clones of the 10 cystinosis
ciPTEC. ATP levels were signiﬁcantly decreased in cystinosis ciPTEC
(2.25±0.36 versus 1.35±0.12; pb0.01), indicating alterations in ATP
metabolism (Fig. 6A). Although in 5 cystinosis ciPTEC there was a
trend towards an increase in intracellular ATP after 48 h of cysteamine
treatment, this increase did not reach statistical signiﬁcance
(p=0.08; Fig. 6B). To determine whether decreased ATP levels
were a result of reduced ATP production, glycolysis and oxidative
phosphorylation were investigated in intact matured cells expressing
either cytosolic or mitochondria targeted luciferase. Neither cytosolic
(glycolysis) nor mitochondrial (oxidative phosphorylation) ATP
production was altered in cystinosis cells (p values of 0.18 and 0.60,
respectively; Fig. 6C). Using glycolysis inhibitors DOG and SIA, ATP
levels were decreased (SIA: N60%; DOG: N90%) in one control and two
cystinosis cell lines, indicating ciPTEC derive their ATP mainly from
glycolysis. Since cultured ciPTEC are mainly glycolytic, we further
explored the glycolytic activity. Both inhibitors signiﬁcantly de-
creased the production of pyruvate in control (DOG: pb0.05; SIA:
pb0.05) and cystinosis (DOG: pb0.05; SIA: pb0.01) ciPTEC. Pyruvate
production was similar in control and cystinosis cells (Fig. 6D).
Next,we addressed thepossibility that decreasedATP levels couldbe
caused by a decreased phosphate availability. Measurement of
intracellular phosphate revealed the absence of any difference between
control and cystinosis ciPTEC (0.22±0.04 versus 0.18±0.01, respec-
tively; p=0.18). Additionally, sodium-dependent phosphate uptake
was determined in ciPTEC, using radio-labeled 32PO4 demonstrating
decreased phosphate uptake in cystinotic cells (pb0.05). By analyzing
Fig. 5. Intracellular ROS production in ciPTEC. (A) Basic CM-H2DCFDA oxidation is not altered in cystinotic ciPTEC. Each point represents a separate cell line of control (n=4) or
cystinotic (n=8) donors, measured in triplo. (B) Control and cystinotic ciPTEC are both sensitive to H2O2-stimulated oxidation of CM-H2DCF. At high levels of H2O2, oxidation was
signiﬁcantly increased in cystinotic cell lines (p values of 0.24; 0.11 and 0.05 for 10; 100 or 1000 μM H2O2, respectively. (C) Flow cytometric analysis of hydroethidine (HEt)
oxidation, showing the absence of any statistically signiﬁcant difference between control and cystinotic ciPTEC. Each point represents a separate cell line of control (n=4) or
cystinotic (n=10) donors, measured in triplo. Gray dots represent cystinotic patients with a homozygous 57 kb deletion.
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aVmax (104.2±15.3 for control and 86.0±5.1 for cystinotic ciPTEC) and
Km (0.15±0.08 and 0.20±0.04, respectively) could be determined
(Fig. 7A). The presence of cysteamine (1mM) did not normalize
phosphate uptake in cystinotic ciPTEC, despite the normalization of
cystine levels (Fig. 7B).Fig. 6. ATP metabolism in ciPTEC. (A) Intracellular levels of ATP are signiﬁcantly
decreased cystinotic ciPTEC. (B) Treatment of cystinotic ciPTEC with 1 mM cysteamine
for 48 h tends to increase intracellular ATP (p=0.08). (C) Measurement of cytosolic
and mitochondrial ATP production using cytosolic and mitochondrial targeted
luciferase, respectively. During luciferin perfusion, ATP-dependent luminescence is
monitored as a measure of ATP production. Cystinotic ciPTEC display normal cytosolic
and mitochondrial ATP production. (D) Pyruvate production as a measure of cytosolic
ATP production in matured ciPTEC incubated in the absence or presence of deoxy-
glucose (DOG) and sodium iodo-acetate (SIA), two potent inhibitors of glycolysis. Both
inhibitors signiﬁcantly decrease glycolytic activity to the same extent in control and
cystinotic ciPTEC. Black bars, control; white bars, cystinosis ⁎pb0.05.4. Discussion and conclusions
In this study, 4 control and 10 cystinosis conditionally immortal-
ized human cell lines were developed from urine of age matched
donors using exfoliated cells of proximal tubular origin. Using this
model, altered GSH redox status and decreased ATP levels were
observed. Moreover, treatment with the cystine depleting agent
cysteamine increased intracellular total GSH levels and restored the
GSH redox status of the cystinosis cells, but did not normalize affected
sodium-dependent phosphate uptake.
The advantage of the presented cell model of cystinosis with
different mutations in CTNS gene is sufﬁcient cystine accumulation,
which is ~37-fold higher compared to control cells, approaching the
levels measured in renal tissue [3]. Furthermore, cystine levels in
cystinosis ciPTEC are approximately 6-fold higher compared to a
previously reported cystinosis PTEC, immortalized using HPV 16 E6/
E7 genes [15]. Probably, the maturation at 37 °C, causing decreased
cell proliferation, allowed the cells to accumulate more cystine over
time. As cells matured for 10 days, continued metabolism and
lysosomal protein digestion could result in more cystine trapped in
the lysosomes. The expression of the temperature sensitive vector
SV40T strongly decreased at 37 °C allowing cells to differentiate. As a
result, the metabolism of the cells was not (or was less) inﬂuenced by
the presence of this viral antigen compared to the other cell models.Fig. 7. Sodium-dependent phosphate uptake in ciPTEC. (A) Phosphate saturation curves in
control (n=4; continuous line) and cystinotic (n=5; dashed line) ciPTEC, demonstrating
decreased phosphate reabsorption in cystinosis (pb0.05). (B) Uptake of 32PO42− was
measured in the presence or absence of cysteamine (1 mM). Cysteamine treatment has no
effect on 32PO42− uptake in control and cystinotic cells. Black bars, control; white bars,
cystinosis.
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were established using the same methodology from pediatric donors,
after similar passage number and in identical phases of the cell cycle,
allowing a valuable comparison of their metabolic status. As the study
population comprises ciPTEC derived from cystinosis patients with
homozygous 57 kb deletion and other mutations in the CTNS gene, a
genotype–phenotype correlation could be further investigated.
However, we neither observed differences in cystine levels nor in
ROS production between the two groups of cells. This is coherent with
the indistinguishable renal phenotype observed in patients having a
homozygous 57 kb deletion compared to other truncating mutations.
In the present study, the effect of cysteamine on GSH status was
studied for the ﬁrst time in a renal cystinosis cell model. Remarkably,
total levels of GSH increased and the GSH redox status normalized
upon cysteamine treatment. In addition to depleting cystine levels,
this indicates that cysteamine acts as an antioxidant, hence, is a
protective agent against oxidative stress. Next to cystine depletion,
this mechanism may underlie the protective action of cysteamine
against the development of interstitial ﬁbrosis, which leads to end
stage renal disease in cystinosis. In line with our ﬁndings, Chol et al.
[9] described a trend towards increased levels in GSH upon incubation
with cysteamine, ornithine and N-acetyl-cysteine. As cysteamine
restores the GSH redox status, this agentmay have beneﬁcial effects in
other disorders associated with increased peroxidation, as oxidative
damage has been proposed to be involved in the pathogenesis in
chronic kidney disease [32,33]. Recently, the use of cysteamine has
also been proven to have a synergistic effect on the anti-malarial
activity of artemisinin-derivatives, implicating the broader use of this
agent [34].
It has been suggested that limited cysteine availability due to
dysfunctional cystine efﬂux from lysosomes in cystinosis was respon-
sible for decreased GSH synthesis via γ-glutamyl cycle [10]. Contrasting
this assumption, we and others demonstrated increased intracellular
levels of cysteine indicating that limited cysteine availability is not the
cause for alterations in γ-glutamyl cycle [35,36]. Elevated free cysteine
levels in cystinosis cells can derive from the extracellular medium or
synthesis frommethionine. A recent studybyBellomoet al. showed that
intracellular cysteine levels regulate the CTNS gene expression [35].
Silencing of the CTNS gene was associated with an increase in
intracellular cysteine comparable to our results in cystinosis ciPTEC.
Interestingly, Foreman et al. demonstrated increased cysteine in CDME
loaded rats,whichdeveloped renal Fanconi syndrome,without elevated
levels of cystine [37]. The mechanism of elevated cysteine in cystinosis
proximal tubular cells should be investigated further.
The formation of GSH from lysosomally accumulated cystine
upon cysteamine treatment can only partially explain elevated GSH
levels, regarding the stochiometry. Free intracellular cysteine
(7.2 mol/mg protein) and intracellular cystine (equal to 2×5.2 mol/
mg protein=10.4 mol cysteine/mg protein) in cystinosis ciPTEC are
3.5-fold lower than required for the increase of GSH (95–34=61 mol
cysteine/mg protein) upon cysteamine treatment. Furthermore,
proximal tubular GSH transporters might be activated by cysteamine,
as tubular GSH levels in vivo are mainly dependent on uptake at the
apical and basolateral membrane via speciﬁc transporters [38,39].
In the cystinosis ciPTEC model, the GSH pool is still sufﬁcient to
protect proteins and fatty acids from oxidative damage at basal
conditions as shown in this study. However, when cystinotic cells are
exposed tohigh levels of oxidation, increasedROSgeneration is observed.
A similar situation can occur in vivo, because of the active oxidative
metabolism in renal proximal tubules, making cystinosis cells prone to
the oxidative stress. Further, in vivo increased protein concentration in
the tubular lumen can exaggerate oxidative stress leading to progressive
tubulo-interstitial inﬂammation [40]. In this situation, intracellular GSH
availability can be of signiﬁcant importance and, therefore, optimal
cysteamine treatment protecting against peroxidation can improve renal
survival. In addition, due to the prominent role of the mitochondrial ATPproduction, an increased ROS production compared to the in vitromodel
can be expected requiringmore GSH for protection. Hence, alterations in
GSH metabolism may induce apoptotic cell death and cause mitochon-
drial oxidative damage [41,42]. Therefore, the various hypotheses with
involvement of GSHmetabolism, ATPmetabolismor enhanced cell death
may represent different facets of a unique cascade leading to tubular
dysfunction initiated by lysosomal cystine accumulation [11,19].
In contrast to our results, a recent study in ﬁbroblasts showed intact
redox status as presented by GSSG/2GSH ratio, with normal total GSH
levels [36]. The latter study correctly pointed towards the difﬁculties in
measuring disulﬁdes and mentioned a possible underestimation of the
total GSH pool in the ﬁbroblasts previously measured by our group [10].
Taken into account that 1 mg protein corresponds to a cell volume of 5 μl
[25], the levelsmeasured inmatured control ciPTEC are 35 nmol GSH/mg
protein/5 μl and equals to 7 mM.Hence, GSH levelsmeasured in cultured
ciPTEC in the current study are comparable to the levels measured in
tubular cells in vivo, which are reported to be in the range of 5 mM [38].
Furthermore, in the current study, the cysteine pool is about 10-fold
lower than the GSH pool in control ciPTEC, which is comparable to other
studies [35,36]. The observed variability in the intracellular thiol
concentration between individual cell lines points to the necessity to
analyze sufﬁcient number of cell lines for making statistically valuable
comparisons.
Inour study, decreased levels of intracellularATP in cystinosis ciPTEC
were observed. Both glycolytic andmitochondrial ATP productionwere
intact, suggesting that decreased ATP levels were a result of increased
ATP consumption. A possible mechanism by which ATP consumption
can be increased in cystinosis was recently suggested by Kumar et al.
[43]. They proposed that a futile turnover of 5-oxoproline to glutamate
in the absence (or decreased availability) of cysteine, consuming two
additional ATP molecules per cycle, might be responsible for the
decreased ATP and explain elevated excretion of 5-oxoproline into
cystinosis urine. As we found no decreased levels of intracellular
cysteine in cystinosis, this mechanism, in our opinion, is not explaining
the observed decrease in ATP. Alternatively, a defect in the Na-
dependent 5-oxoproline transporter in renal proximal tubules might
be responsible for the increased excretion of this metabolite [44]. The
artiﬁcial loading with CDME was recently used by Figueiredo et al. to
demonstrate decreased adenylate cyclase activity [45]. They suggested
that cystine inhibition of this enzyme, catalyzing the phosphate transfer
between ATP and AMP, could be partially responsible for the observed
ATP decrease in cystinosis cells. In our present study, we showed that
cysteamine treatment did not improve cellular phosphate uptake
despite slight increase of intracellular ATP levels, implicating that
elevated cystine levels are not directly associated defective proximal
tubular reabsorption. The latter observation corresponds to persistence
of Fanconi syndrome in vivo in cystinosis patients despite cysteamine
therapy [46]. Moreover, these ﬁndings demonstrate again that the
CDME loading technique is of limited value in studying thepathogenesis
of cystinosis [18].
Defective albumin uptake, another feature of Fanconi syndrome,
could not be demonstrated in the cystinotic ciPTEC model. This is in
line with our previous study demonstrating both intact apical
expression of megalin together with abundant endocytic vesicles
containing albumin and other megalin ligands in human cystinotic
kidney tissue [47]. Thus, the origin of proteinuria can be different in
cystinosis compared to other pathological conditions manifesting
with renal Fanconi syndrome, such as Dent disease, in which apical
expression of megalin in PTEC is decreased [48].
Taken together, the identical preparation of four control and ten
cystinosis ciPTEC in the present study allows valid and detailed in vitro
investigation of cell metabolism involved in the pathogenesis of
cystinosis. Using this model, increased oxidation of GSH was demon-
strated resulting in altered intracellular redox status in cystinosis cells.
Cysteamine increased intracellular GSH levels and restored redox status
of GSSG/2GSH couple. This mechanism may be responsible for better
650 M.J. Wilmer et al. / Biochimica et Biophysica Acta 1812 (2011) 643–651conservation of renal function in cystinosis patients treated with
cysteamine. The increase of intracellular GSH in control cells upon
cysteamine treatment points to the possibility of using this amino thiol
in other renal disorders associated with enhanced oxidative stress.Acknowledgements
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